The Goldman Sachs Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Key Points

• Goldman Sachs cut its Ultragenyx price target from $19 to $17 and maintained a neutral rating, implying about 3% downside from the stock’s then-current price.
• Third-quarter revenue rose 8.2% year over year to $173 million and the per-share loss narrowed, but both revenue and EPS missed analyst expectations.
• The company reaffirmed its 2026 revenue and 2027 profitability outlook, citing cost reductions; it also reported FDA approvals for two products and agreements to sell two priority review vouchers for $413 million combined.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its price target decreased by research analysts at The Goldman Sachs Group from $19.00 to $17.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's target price would indicate a potential downside of 2.96% from the company's current price.

A number of other research analysts also recently commented on the company. UBS Group started coverage on Ultragenyx Pharmaceutical in a report on Thursday, October 15th. They set a "neutral" rating and a $16.00 target price on the stock. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Friday, September 18th. Cantor Fitzgerald lifted their price target on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the company an "overweight" rating in a report on Friday, September 18th. Wall Street Zen raised Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Evercore cut Ultragenyx Pharmaceutical from an "outperform" rating to an "in-line" rating and set a $16.00 target price on the stock. in a report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $33.55.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.89 during midday trading on Wednesday, reaching $17.52. 2,857,596 shares of the company's stock traded hands, compared to its average volume of 2,851,260. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89. The business has a 50-day moving average price of $16.64 and a two-hundred day moving average price of $22.81. The company has a market capitalization of $1.73 billion, a P/E ratio of -3.00 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same quarter in the previous year, the company posted ($1.81) earnings per share. The company's revenue for the quarter was up 8.2% on a year-over-year basis. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -4.30 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of the business's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer owned 89,229 shares in the company, valued at $1,362,526.83. The trade was a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 8,510 shares of company stock worth $127,561. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RARE. Commonwealth Equity Services LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $661,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $76,000. Profund Advisors LLC boosted its position in shares of Ultragenyx Pharmaceutical by 49.4% during the 3rd quarter. Profund Advisors LLC now owns 76,847 shares of the biopharmaceutical company's stock worth $1,155,000 after acquiring an additional 25,397 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 14.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,989 shares of the biopharmaceutical company's stock worth $276,000 after acquiring an additional 2,314 shares in the last quarter. Finally, Sterling Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 102.4% in the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 1,252 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The company reaffirmed its 2026 revenue and 2027 profitability outlook, and said cost reductions are expected to cut 2027 R&D expenses by at least 50% compared with 2025. Company results and outlook
• Positive Sentiment: Ultragenyx said the FDA approved GENGLYCOS and FAYUVI during the quarter. It also entered agreements to sell two priority review vouchers for a combined $413 million, adding a significant potential source of proceeds. Company results and outlook
• Positive Sentiment: Revenue increased 8.2% year over year to $173 million, while the quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Third-quarter results
• Neutral Sentiment: Analyst target revisions were mixed: Wells Fargo raised its target from $18 to $19 and kept an equal-weight rating, while Wedbush lowered its target from $25 to $22 and maintained a neutral rating.
• Negative Sentiment: Despite year-over-year improvement, Q3 results missed expectations: the $1.16-per-share loss was wider than analysts’ roughly $1.10 estimate, and $173 million in revenue was below the $182.49 million consensus. Q3 earnings report

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.